---
title: "Allovir (ALVR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ALVR.US.md"
symbol: "ALVR.US"
name: "Allovir"
industry: "Biotechnology"
---

# Allovir (ALVR.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VS...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.84 | 230/604 | - | - | - |
| PB | 0.43 | 68/604 | 0.43 | 0.43 | 0.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.81 |
| Highest Target | 34.50 |
| Lowest Target | 34.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/ALVR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ALVR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ALVR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.